Key result
Pulse wave velocity is a recognized marker of arterial stiffness and cardiovascular risk in COPD, though data on its reproducibility in this population remain lacking.
Highlights the lack of and need for studies evaluating the variability and reproducibility of pulse wave velocity in patients with COPD.
Arterial stiffness by pulse wave velocity in COPD: reliability and reproducibilityTo the Editor: Cardiovascular diseases are the most common cause of mortality in chronic obstructive pulmonary disease (COPD) [1].Arterial stiffness certainly plays a role in the increased cardiovascular risk of these patients [2,3].Arterial pulse wave velocity (PWV) constitutes a useful and safe non-invasive method [4] for assessing central arterial stiffness.The carotid-femoral PWV is considered as the gold standard method by the European Society of Hypertension/European Society of Cardiology [5] and is a strong predictor of future cardiovascular events and all-cause mortality, supporting its implementation into clinical research and daily practice [6].In patients with COPD, feasibility and validity of this marker of arterial stiffness have been confirmed [2] and PWV is now used in studies evaluating cardiovascular risk and/or the efficacy of new bronchodilators and rehabilitation programmes [3,7,8].However, little is known about its variability and reproducibility studies are lacking in the COPD population.
No takes yet. Share an insight, caveat, or question.
Vivodtzev et al. (2013) conducted a letter in COPD. Pulse wave velocity was evaluated. Pulse wave velocity is a recognized marker of arterial stiffness and cardiovascular risk in COPD, though data on its reproducibility in this population remain lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: